MedTrace Logo

Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy

NCT07162454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-10-01

No results posted yet for this study

Summary

Evaluation of cannabidiol and urea 10%.

Conditions

  • Xerosis Cutis
  • Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Interventions

DRUG

Group 1. Complete formula

After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.

DRUG

Group 2. Cannabidiol and Urea 10% formula.

After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.

DRUG

Group 3. Placebo formula.

Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.

Sponsors & Collaborators

  • Universidad Complutense de Madrid

    lead OTHER

Principal Investigators

  • José Luis Lázaro Martinez, Podiatrist · Clínica Universitaria de podología de la Universidad Complutense de Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-05-31
Completion
2025-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07162454 on ClinicalTrials.gov